Chronic somatostatin treatment affects pituitary gonadotrophs, ovaries and onset of puberty in rats.
The effects of chronic somatostatin (SRIH-14) treatment on the pituitary gonadotrophs (FSH and LH cells) and ovaries of female Wistar rats were examined. Females were given 20 microg/100 g b.w. twice per day from the immature (23rd day) till the adult period of life (71st day). The onset of puberty was determined by daily examination for vaginal opening. The peroxidase-antiperoxidase immunocytochemical procedure was used to study the gonadotrophs. Changes in the number per unit area (mm2), cell volume and volume densities of LH- and FSH-immunoreactive cells were evaluated by morphometry and stereology. Ovaries were analysed by simple point counting of follicles and corpora lutea (CL). Follicles were divided by size according to the classification of Gaytán and Osman. The mitotic indexes of granulosa and theca cells in the follicles were estimated at all stages of folliculogenesis. The number, volume and the volume density of FSH- and LH-immunoreactive cells decreased after chronic SRIH-14 treatment, particularly the latter. In the ovary, SRIH-14 treatment decreased the number of healthy follicles at all phases of folliculogenesis, lowered the mitotic indexes of granulosa and theca cells but increased the number of atretic follicles. Healthy CL were fewer in number, while regressive CL were increased. Vaginal opening occurred at a later age in treated females. It can be concluded that chronic SRIH-14 treatment markedly inhibited LH cells and to a lesser extent FSH cells. In the ovary SRIH-14 inhibited folliculogenesis, enhanced atretic processes and lowered proliferative activity of granulosa and theca cells. It also delayed puberty onset.
Nestorović
N
N
Institute for Biological Research, 29. November 142, 11060 Belgrade, Serbia and Montenegro. rnata@ibiss.bg.ac.yu
Lovren
M
M
Sekulić
M
M
Negić
N
N
Sosić-Jurjević
B
B
Filipović
B
B
Milosević
V
V
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D003338:Corpus Luteum / Q000187:drug effects; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006062:Gonadotropins / Q000378:metabolism; D006107:Granulosa Cells / Q000187:drug effects / Q000378:metabolism; D007150:Immunohistochemistry; D007986:Luteinizing Hormone / Q000378:metabolism; D008938:Mitosis / Q000187:drug effects; D008940:Mitotic Index; D006080:Ovarian Follicle / Q000166:cytology / Q000187:drug effects; D010053:Ovary / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010902:Pituitary Gland / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012741:Sexual Maturation / Q000187:drug effects*; D013004:Somatostatin / Q000494:pharmacology*; D013799:Theca Cells / Q000187:drug effects / Q000378:metabolism
D006062:Gonadotropins; D013004:Somatostatin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone